Study on the impact of the specialized centralized procurement for insulin on the daily cost and affordability of insulin in China
- VernacularTitle:胰岛素专项集采对我国胰岛素日费用和可负担性的影响研究
- Author:
Fengping LEI
1
,
2
;
Jieqiong ZHANG
1
,
3
;
Xingchen LIU
1
;
Haoqi WEI
1
;
Xingyu LIU
1
;
Caijun YANG
1
Author Information
1. School of Pharmacy，Xi’an Jiaotong University，Xi’an 710061，China
2. Dept. of Pharmacy，Xi’an Aerospace Hospital，Xi’an 710100，China
3. Yixing Life and Health Industry Innovation Service Center，Jiangsu Wuxi 214000，China
- Publication Type:Journal Article
- Keywords:
insulin;
national centralized procurement;
daily cost;
affordability
- From:
China Pharmacy
2025;36(12):1483-1487
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the impact of the specialized centralized procurement policy for insulin on daily cost and affordability of insulin， and provide data support for the enhancement of relevant policies. METHODS In this research， the insulin purchasing data were obtained from provincial centralized procurement platforms in provinces before and after the specialized centralized procurement of insulin （October-December 2021 and October-December 2022）， and the cost variations of insulin before and after the centralized procurement were analyzed by the defined daily dose cost （DDDc） of various types of insulins. The changes in the affordability of various types of insulins before and after the specialized centralized procurement were evaluated， using the percentage of annual expenditure on various types of insulins relative to annual per capita disposable income （i.e. the proportion of annual expenditure） as an indicator. RESULTS After the specialized centralized procurement， DDDc of various types of insulins decreased by 20.7%-71.8%， with an average reduction of 45.7%. Moreover， the reduction in DDDc for third-generation insulin exceeded that for second-generation insulin. The reduction in the proportion of annual expenditure on insulin ranged from 24.3% to 73.4%， with an average decrease of 48.5%. Premixed insulin analogs experienced the greatest reduction （73.4%）. Following the specialized centralized procurement， DDDc of insulin decreased in all provinces. Except for Guangxi （10.2%）， the average proportion of annual expenditure on insulin in the remaining provinces dropped to below 10%. CONCLUSIONS The specialized centralized procurement policy for insulin has significantly reduced insulin costs and improved affordability， thereby alleviating the economic pressure on patients with diabetes. There are notable cost disparities among provinces and among insulin categories， which require attention.
